Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

<p>Raw data provided by Nanostring bioinformatic team</p>

Збережено в:

Бібліографічні деталі
Автор:	Yeh Wang (14964041) (author)
Інші автори:	Peng Huang (14964044) (author), Brant G. Wang (14964047) (author), Tricia Murdock (14964050) (author), Leslie Cope (14964053) (author), Fang-Chi Hsu (14964056) (author), Tian-Li Wang (14964059) (author), Ie-Ming Shih (14964062) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Risk Factors Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Cancer Prevention Biomarkers Early detection biomarkers Cancer Interception Biomarkers and intervention Carcinogenesis Tumor initiation and promotion Epigenetics DNA methylation Gynecological Cancers Ovarian cancer Tumor Evolution
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
за авторством: Yeh Wang (14964041)
Опубліковано: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
за авторством: Raphaël Leman (17314506)
Опубліковано: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
за авторством: Nicola S. Meagher (15048462)
Опубліковано: (2025)

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
за авторством: Christopher J. Gibson (15907642)
Опубліковано: (2025)

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
за авторством: Christopher J. Gibson (15907642)
Опубліковано: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
за авторством: Katleen Janssens (15053356)
Опубліковано: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
за авторством: Félix Blanc-Durand (15049400)
Опубліковано: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
за авторством: Jun Wang (15051911)
Опубліковано: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
за авторством: Sanna Pikkusaari (15055802)
Опубліковано: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
за авторством: Colin S. Wood (15293247)
Опубліковано: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
за авторством: Athanasios Bikas (16006076)
Опубліковано: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
за авторством: Daniel S. Green (15047598)
Опубліковано: (2025)

Supplementary file 3: Supplementary Tables. from circFNDC3B Accelerates Vasculature Formation and Metastasis in Oral Squamous Cell Carcinoma
за авторством: Xiang Li (15386727)
Опубліковано: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
за авторством: Laura Privitera (16015972)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_63peo3qkd3std2hpbe6tavemj0